AB154 Combined With AB122 for Recurrent Glioblastoma
AB154 Combined With AB122 for Recurrent Glioblastoma
Active, not recruiting · NCT04656535 · Registry updated 2026-04-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| AB154 Combined With AB122 for Recurrent Glioblastoma | Disease Attributes, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Early phase 1 | 2026-04-17 | NCT04656535 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Arcus Biosciences, Inc. | 27 |
| National Cancer Institute (NCI) | 3015 |
| Yale University | 458 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| University of California San Francisco | San Francisco | United States | 144 |
| Yale University | New Haven | United States | 29 |